Elite Pharmaceuticals Inc. Reports 48% Revenue Increase to $84 Million for Fiscal Year Ending March 31, 2025, Driven by Product Launches and Elite Label Sales

Reuters
Jul 01
Elite Pharmaceuticals Inc. Reports 48% Revenue Increase to $84 Million for Fiscal Year Ending March 31, 2025, Driven by Product Launches and Elite Label Sales

Elite Pharmaceuticals Inc. has reported significant financial results for the fiscal year ended March 31, 2025. The company's total revenues saw an impressive increase of $27.4 million, or 48%, reaching $84.0 million compared to $56.6 million in the previous year. This substantial growth was primarily driven by four product launches during the current fiscal year, alongside boosted sales from the Elite Label product line. Manufacturing fees revenue experienced a notable rise of $27.9 million, or 51%, compared to the previous year, largely due to the same factors contributing to the overall revenue growth. In contrast, licensing fees revenue saw a decline of $0.4 million, or 18%, as the company shifted away from licensing products to third parties. On the expenses front, research and development costs increased by $1.1 million, or 16%, totaling $8.0 million, while general and administrative expenses rose by $1.9 million, or 26%, amounting to $9.0 million. The company did not provide outlook or guidance for future periods in the report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017134), on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10